JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
technique to inject very small amounts of beneficial chemicals into the scalp
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
highly targeted anti-androgen that might have minimal systemic effects
precursor of vitamin B5 with hair stimulating effects
- Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.